These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

180 related items for PubMed ID: 15039452

  • 1. Metformin causes reduction of food intake and body weight gain and improvement of glucose intolerance in combination with dipeptidyl peptidase IV inhibitor in Zucker fa/fa rats.
    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2004 Aug; 310(2):614-9. PubMed ID: 15039452
    [Abstract] [Full Text] [Related]

  • 2. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Saeki T, Tanaka I.
    Eur J Pharmacol; 2004 Mar 19; 488(1-3):213-8. PubMed ID: 15044053
    [Abstract] [Full Text] [Related]

  • 3. Enteroinsular axis of db/db mice and efficacy of dipeptidyl peptidase IV inhibition.
    Nagakura T, Yasuda N, Yamazaki K, Ikuta H, Tanaka I.
    Metabolism; 2003 Jan 19; 52(1):81-6. PubMed ID: 12524666
    [Abstract] [Full Text] [Related]

  • 4. Improvement of glucose tolerance in Zucker diabetic fatty rats by long-term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with rosiglitazone.
    Wargent E, Stocker C, Augstein P, Heinke P, Meyer A, Hoffmann T, Subramanian A, Sennitt MV, Demuth HU, Arch JR, Cawthorne MA.
    Diabetes Obes Metab; 2005 Mar 19; 7(2):170-81. PubMed ID: 15715890
    [Abstract] [Full Text] [Related]

  • 5. Acute and chronic effects of the incretin enhancer vildagliptin in insulin-resistant rats.
    Burkey BF, Li X, Bolognese L, Balkan B, Mone M, Russell M, Hughes TE, Wang PR.
    J Pharmacol Exp Ther; 2005 Nov 19; 315(2):688-95. PubMed ID: 16027230
    [Abstract] [Full Text] [Related]

  • 6. 7-But-2-ynyl-9-(6-methoxy-pyridin-3-yl)-6-piperazin-1-yl-7,9-dihydro-purin-8-one is a novel competitive and selective inhibitor of dipeptidyl peptidase IV with an antihyperglycemic activity.
    Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Shinoda M, Saeki T, Tanaka I.
    J Pharmacol Exp Ther; 2006 Dec 19; 319(3):1253-7. PubMed ID: 16980568
    [Abstract] [Full Text] [Related]

  • 7. Dipeptidyl peptidase IV inhibitors for the treatment of impaired glucose tolerance and type 2 diabetes.
    Wiedeman PE, Trevillyan JM.
    Curr Opin Investig Drugs; 2003 Apr 19; 4(4):412-20. PubMed ID: 12808880
    [Abstract] [Full Text] [Related]

  • 8. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N, McClean PL, Flatt PR.
    J Pept Sci; 2007 Jun 19; 13(6):400-5. PubMed ID: 17486662
    [Abstract] [Full Text] [Related]

  • 9. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD, Lavery KS, Irwin N, O'harte FP, Harriott P, Greer B, Bailey CJ, Flatt PR.
    J Pharmacol Exp Ther; 2006 Aug 19; 318(2):914-21. PubMed ID: 16648370
    [Abstract] [Full Text] [Related]

  • 10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y, Kwon MK, Kang ES, Park YM, Choi SH, Ahn CW, Kim KS, Park CW, Cha BS, Kim SW, Sung JK, Lee EJ, Lee HC.
    J Gene Med; 2008 Mar 19; 10(3):260-8. PubMed ID: 18085721
    [Abstract] [Full Text] [Related]

  • 11. Dipeptidyl peptidase IV inhibitors: a promising new therapeutic approach for the management of type 2 diabetes.
    Deacon CF, Holst JJ.
    Int J Biochem Cell Biol; 2006 Mar 19; 38(5-6):831-44. PubMed ID: 16242377
    [Abstract] [Full Text] [Related]

  • 12. Combination of dipeptidylpeptidase IV inhibitor and low dose thiazolidinedione: preclinical efficacy and safety in db/db mice.
    Roy S, Khanna V, Mittra S, Dhar A, Singh S, Mahajan DC, Priyadarsiny P, Davis JA, Sattigeri J, Saini KS, Bansal VS.
    Life Sci; 2007 Jun 13; 81(1):72-9. PubMed ID: 17532347
    [Abstract] [Full Text] [Related]

  • 13. (2S,4S)-4-Fluoro-1-{[(2-hydroxy-1,1-dimethylethyl)amino]acetyl}-pyrrolidine-2-carbonitrile monobenzenesulfonate (TS-021) is a selective and reversible dipeptidyl peptidase IV inhibitor.
    Tajima A, Yamamoto K, Kozakai A, Okumura-Kitajima L, Mita Y, Kitano K, Jingu S, Nakaike S.
    Eur J Pharmacol; 2011 Mar 25; 655(1-3):99-107. PubMed ID: 21262219
    [Abstract] [Full Text] [Related]

  • 14. Enhanced secretion of glucagon-like peptide 1 by biguanide compounds.
    Yasuda N, Inoue T, Nagakura T, Yamazaki K, Kira K, Saeki T, Tanaka I.
    Biochem Biophys Res Commun; 2002 Nov 15; 298(5):779-84. PubMed ID: 12419322
    [Abstract] [Full Text] [Related]

  • 15. DPP-4 inhibitors and GLP-1 analogues: for whom? Which place for incretins in the management of type 2 diabetic patients?
    Halimi S.
    Diabetes Metab; 2008 Feb 15; 34 Suppl 2():S91-5. PubMed ID: 18640591
    [Abstract] [Full Text] [Related]

  • 16. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes.
    Brazg R, Xu L, Dalla Man C, Cobelli C, Thomas K, Stein PP.
    Diabetes Obes Metab; 2007 Mar 15; 9(2):186-93. PubMed ID: 17300594
    [Abstract] [Full Text] [Related]

  • 17. Dipeptidyl peptidase-4 inhibitors administered in combination with metformin result in an additive increase in the plasma concentration of active GLP-1.
    Migoya EM, Bergeron R, Miller JL, Snyder RN, Tanen M, Hilliard D, Weiss B, Larson P, Gutierrez M, Jiang G, Liu F, Pryor KA, Yao J, Zhu L, Holst JJ, Deacon C, Herman G, Thornberry N, Amatruda J, Williams-Herman D, Wagner JA, SinhaRoy R.
    Clin Pharmacol Ther; 2010 Dec 15; 88(6):801-8. PubMed ID: 21048706
    [Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
    Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P, Sitagliptin Study 035 Group.
    Diabetes Obes Metab; 2007 Sep 15; 9(5):733-45. PubMed ID: 17593236
    [Abstract] [Full Text] [Related]

  • 19. K579, a slow-binding inhibitor of dipeptidyl peptidase IV, is a long-acting hypoglycemic agent.
    Takasaki K, Iwase M, Nakajima T, Ueno K, Nomoto Y, Nakanishi S, Higo K.
    Eur J Pharmacol; 2004 Feb 23; 486(3):335-42. PubMed ID: 14985056
    [Abstract] [Full Text] [Related]

  • 20. Effect of sitagliptin plus metformin on β-cell function, islet integrity and islet gene expression in Zucker diabetic fatty rats.
    Han SJ, Choi SE, Kang Y, Jung JG, Yi SA, Kim HJ, Lee KW, Kim DJ.
    Diabetes Res Clin Pract; 2011 May 23; 92(2):213-22. PubMed ID: 21345512
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.